Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) Including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt's and Atypical Burkitt's Lymphoma

NCT00392834 is registered in ClinicalTrials.gov with AIDS Malignancy Consortium as lead sponsor.

NCT NCT00392834
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00392834 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) Including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt's and Atypical Burkitt's Lymphoma
Lead sponsor
AIDS Malignancy Consortium
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2006
Completion date
July 31, 2013
Enrollment
34 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma